Humana · Semaglutide · US health-plan appeal rights

Semaglutide denied as experimental or investigational by Humana?

Q: How long do I have to appeal a Humana Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

At a glance

Why does Humana label semaglutide "experimental"?

Wrong on its face for branded Wegovy/Ozempic. Usually points at compounded semaglutide, off-label dose (>2.4mg), or a Part D plan flagging non-covered obesity indications.

How do I overturn a Humana commercial experimental denial on branded?

Cite Wegovy NDA 215256, Ozempic NDA 209637. Attach FDA approval letter. Most reverse on first re-submission.

For Humana MA Part D experimental denials?

Verify whether the denial is truly "experimental" or actually a Part D obesity exclusion (42 USC §1395w-102(e)(2)(A)) miscategorized. The fix differs.

For compounded?

Pivot to branded. Humana follows FDA October 2024 guidance — compounded GLP-1s remain experimental on appeal.

What's the strongest Humana MA pathway?

After redetermination denial, file IRE reconsideration immediately under 42 CFR §423.602. IRE overturn rates substantially exceed Humana's internal review.

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

BMI >=30, OR BMI >=27 with comorbidity. Step therapy: phentermine or phentermine/topiramate trial unless contraindicated.

Source policy: Pharmacy Policy: Weight Loss Agents

What works in the appeal

Step-therapy exemption per 42 CFR 422.568 + state parity laws: contraindications include HTN, CAD, hyperthyroidism, agitation, MAO-I (phentermine); glaucoma, metabolic acidosis, pregnancy (topiramate). Cost-effectiveness: cite Hill et al 2024 (Obesity Reviews).

The Humana angle on Semaglutide

Humana labeling semaglutide "experimental/investigational" is wrong on its face — semaglutide has FDA approval for both T2DM (Ozempic, NDA 209637, December 2017) and chronic weight management (Wegovy, NDA 215256, June 2021, expanded March 2024 for cardiovascular risk reduction). When Humana uses experimental coding, it's usually pointing at one of three things: (1) compounded semaglutide, (2) off-label dose, or (3) a Part D plan flagging non-covered obesity indications miscategorized as experimental.

Diagnose which one before drafting:

Compounded. Humana treats compounded semaglutide as experimental categorically, consistent with FDA October 2024 guidance on compounded GLP-1s. The appeal needs to argue medical necessity for branded Wegovy/Ozempic instead — compounded coverage is essentially never overturned on appeal.
Off-label dose. Humana sometimes treats above-FDA-label dosing (e.g., titrating beyond 2.4mg weekly) as experimental. Confirm the prescribed dose matches the FDA label exactly, or argue medical necessity for the off-label dose with peer-reviewed evidence (which is thin above 2.4mg).
Indication-based. For Humana MA Part D, verify whether the "experimental" denial is actually a Part D obesity exclusion (42 USC §1395w-102(e)(2)(A)) miscategorized as experimental. The fix differs — for true Part D exclusion, pivot to T2DM (Ozempic) or cardiovascular indication.

For Humana commercial confusion errors on branded Wegovy or Ozempic, attach the FDA label and approval letter. Most reverse on first re-submission with FDA documentation attached.

The federal regulatory hook for Humana commercial: ERISA §503's reviewer specialty requirement (29 CFR §2560.503-1(b)(2)) for self-funded plans. Request endocrinology or obesity medicine reviewer. Self-funded ERISA Humana plans must produce evidence supporting the experimental classification — not the patient's burden to disprove (cf. Pinto v. Aetna line of ERISA case law).

For Humana Medicare Advantage plans, the federal hook is stronger: CMS rules under 42 CFR §422.566 require Humana to follow CMS-defined coverage standards. Experimental designation contrary to FDA approval is appealable to the Independent Review Entity (IRE) under 42 CFR §423.602. IRE overturn rates substantially exceed Humana's internal review.

The Humana-specific procedural lever: CarelonRx for commercial; Humana Pharmacy Solutions for MA. Wrong-channel submissions trigger automatic denial. Pull from the patient's pharmacy ID card before submitting.

Closing tactical tip: for Humana MA experimental denials, file the IRE request immediately on redetermination denial — don't wait through additional internal Humana review. The IRE reviews independently and overturns at substantially higher rates.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other insurers on Semaglutide

Other denial reasons for Humana Semaglutide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.